Evolus (NASDAQ:EOLS) Stock Price Down 13%

Evolus, Inc. (NASDAQ:EOLSGet Rating) fell 13% during mid-day trading on Tuesday . The company traded as low as $11.40 and last traded at $11.40. 7,161 shares changed hands during trading, a decline of 98% from the average session volume of 352,367 shares. The stock had previously closed at $13.11.

Analyst Ratings Changes

A number of research firms recently issued reports on EOLS. Barclays raised Evolus from an “underweight” rating to an “equal weight” rating and raised their price target for the stock from $8.00 to $10.00 in a report on Thursday, May 12th. Needham & Company LLC initiated coverage on Evolus in a report on Thursday, June 23rd. They set a “buy” rating and a $18.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Evolus Price Performance

The stock has a fifty day simple moving average of $12.37 and a two-hundred day simple moving average of $10.84. The company has a market cap of $536.95 million, a PE ratio of -7.37 and a beta of 1.95. The company has a current ratio of 3.51, a quick ratio of 3.42 and a debt-to-equity ratio of 1.06.

Evolus (NASDAQ:EOLSGet Rating) last announced its quarterly earnings results on Tuesday, May 10th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.15. The business had revenue of $33.90 million for the quarter, compared to analyst estimates of $29.83 million. Evolus had a negative return on equity of 80.20% and a negative net margin of 58.28%. The company’s quarterly revenue was up 177.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.16 EPS. On average, equities analysts predict that Evolus, Inc. will post -1.07 EPS for the current fiscal year.

Insider Transactions at Evolus

In other news, insider David Moatazedi sold 55,321 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $13.64, for a total transaction of $754,578.44. Following the sale, the insider now owns 491,961 shares of the company’s stock, valued at approximately $6,710,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director David N. Gill sold 5,313 shares of Evolus stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $13.10, for a total transaction of $69,600.30. Following the completion of the transaction, the director now directly owns 34,568 shares in the company, valued at approximately $452,840.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Moatazedi sold 55,321 shares of Evolus stock in a transaction that occurred on Monday, May 16th. The stock was sold at an average price of $13.64, for a total value of $754,578.44. Following the transaction, the insider now owns 491,961 shares of the company’s stock, valued at $6,710,348.04. The disclosure for this sale can be found here. Insiders have sold 143,649 shares of company stock valued at $1,883,585 in the last quarter. 7.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EOLS. Strs Ohio raised its position in shares of Evolus by 31.3% during the 4th quarter. Strs Ohio now owns 74,300 shares of the company’s stock worth $483,000 after purchasing an additional 17,700 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Evolus during the 4th quarter worth approximately $89,000. Nisa Investment Advisors LLC raised its position in shares of Evolus by 945.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,750 shares of the company’s stock worth $43,000 after purchasing an additional 5,200 shares during the last quarter. Monarch Partners Asset Management LLC raised its position in shares of Evolus by 9.2% during the 4th quarter. Monarch Partners Asset Management LLC now owns 166,119 shares of the company’s stock worth $1,081,000 after purchasing an additional 14,059 shares during the last quarter. Finally, Potomac Capital Management Inc. acquired a new position in Evolus in the 4th quarter valued at $863,000. 36.94% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

(Get Rating)

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

See Also

Want More Great Investing Ideas?

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.